Oxford Biomedica (OXB) RNS Announcements

Add to Alert list
Date Time Source Announcement
26 Feb 2021 10:46 AM
RNS
PDMR Dealings / Market Share sale
05 Feb 2021 01:22 PM
RNS
Holdings in Company
03 Feb 2021 07:00 AM
RNS
Board Changes
01 Feb 2021 09:47 AM
RNS
Total Voting Rights
18 Jan 2021 04:34 PM
RNS
Prime Minister Boris Johnson formally opens Oxbox
04 Jan 2021 02:09 PM
RNS
Block Listing Return
04 Jan 2021 01:41 PM
RNS
Total Voting Rights
30 Dec 2020 09:03 AM
RNS
OXB notes AZ vaccine has been authorised in the UK
01 Dec 2020 12:17 PM
RNS
Director Dealings
01 Dec 2020 09:02 AM
RNS
Total Voting Rights
23 Nov 2020 08:47 AM
RNS
OXB notes AZD1222 met primary efficacy endpoint
23 Nov 2020 07:00 AM
RNS
Non-Executive Director Appointment
09 Nov 2020 07:00 AM
RNS
OXB and PhoreMost enter gene therapy collaboration
02 Nov 2020 09:02 AM
RNS
Total Voting Rights
30 Oct 2020 07:00 AM
RNS
Axovant update on AXO-Lenti-PD and virtual R&D day
23 Oct 2020 10:27 AM
RNS
Director Purchase
12 Oct 2020 05:38 PM
RNS
Holding(s) in Company
06 Oct 2020 12:46 PM
RNS
Axovant update on 2nd cohort of SUNRISE-PD trial
06 Oct 2020 07:00 AM
RNS
OXB receives approval for fourth suite in Oxbox
05 Oct 2020 10:59 AM
EQS
Oxford Biomedica (OXB): Vector innovation key t...
02 Oct 2020 11:52 AM
RNS
Total Voting Rights
29 Sep 2020 03:51 PM
RNS
Director Dealings
24 Sep 2020 09:36 AM
RNS
Director/PDMR Shareholding
22 Sep 2020 12:54 PM
RNS
Director/PDMR Shareholding
17 Sep 2020 07:00 AM
RNS
Interim Results
01 Sep 2020 09:33 AM
RNS
Total Voting Rights
01 Sep 2020 07:00 AM
RNS
Master Supply and Development Agreement with AZ
27 Aug 2020 07:00 AM
RNS
Notice of Interim Results
25 Aug 2020 04:46 PM
RNS
Block listing Application
03 Aug 2020 09:41 AM
RNS
Total Voting Rights
03 Aug 2020 07:00 AM
RNS
OXB signs DMLA with Beam Therapeutics
31 Jul 2020 07:00 AM
RNS
OXB Signs Clinical Supply Agreement with Axovant
20 Jul 2020 04:23 PM
RNS
OXB notes interim results from AZ on AZD1222
03 Jul 2020 10:45 AM
RNS
Director Dealings / Market Share Purchase
02 Jul 2020 03:39 PM
RNS
Director Dealings / Market Share Purchase
02 Jul 2020 01:34 PM
RNS
Director Dealings / Market Share Transactions
01 Jul 2020 06:30 PM
RNS
Holdings in Company
01 Jul 2020 03:44 PM
RNS
Block listing Return
01 Jul 2020 09:13 AM
RNS
Total Voting Rights
30 Jun 2020 03:23 PM
RNS
Grant of options
25 Jun 2020 09:44 AM
RNS
Holding(s) in Company
24 Jun 2020 11:45 AM
RNS
Holdings in Company
24 Jun 2020 09:54 AM
RNS
Director Dealings / Share Disposal - Replacement
24 Jun 2020 07:00 AM
RNS
Director Dealings / Market Share Purchase
23 Jun 2020 04:46 PM
RNS
Result of Annual General Meeting
23 Jun 2020 02:47 PM
RNS
Admission of shares and Total Voting Rights.
23 Jun 2020 07:00 AM
RNS
Annual General Meeting
19 Jun 2020 03:26 PM
RNS
Information in Relation to Annual General Meeting
19 Jun 2020 07:00 AM
RNS
Result of Placing
18 Jun 2020 05:33 PM
RNS
Proposed Placing of new Ordinary Shares

Oxford Biomedica is a company that specialises in cell and gene therapy, and is a leader in the development of gene-based medicines. They work with pharmaceutical and biotechnology companies to develop and manufacture viral vectors, including lentivirus, adeno-associated virus, and adenoviral vectors.

Headquartered in Oxford, Oxford Biomedica has manufacturing facilities in Oxfordshire, UK, Lyon and Strasbourg, France, and near Boston, MA, US.

Oxford Biomedica share price listed in London under the ticker OXB at 2,570p.

UK 100

Latest directors dealings